We Are Motley. A Message of Solidarity From The Motley Fool. The research is aimed at providing the Food and Drug Administration with scientific data on the substance. Charlotte’s Web (OTC:CWBH.F) is putting its money where its mouth is with cannabidiol (CBD). The company, which specializes in “wellness” products made from the substance, announced Tuesday…
We Are Motley. A Message of Solidarity From The Motley Fool.
Charlotte’s Web( OTC: CWBH.F) is putting its cash where its mouth is with cannabidiol (CBD). The business, which specializes in “health” products made from the compound, revealed Tuesday it is sponsoring a research study on the effects of CBD. It did not specify how much it is contributing with this sponsorship.
The research study, being carried out by privately held clinical research company ValidCare, is focused on identifying whether and how everyday CBD usage affects the body. Further information of the scheduled research study, including its timing, were not supplied.
Image source: Getty Images.
Seven marijuana companies active in the CBD section, including Charlotte’s Web, are involved in the study. Of the seven, Charlotte’s Web is the just one that is openly traded.
The research push comes from a demand from the Food and Drug Administration seeking science-based data on CBD to assist guide its regulative approach to the substance. Last November, the FDA published a consumer upgrade on CBD items, alerting that their usage could lead to health issue such as liver injury, among other problems.
” As the marketplace share leader, anchored in science, sponsoring ValidCare’s study made strategic sense for us,” Charlotte’s Web composed in its news release declaring its participation. “This research study will offer important scientific information to guide our entire market while likewise showing the FDA we’ve heard their demands and are answering their questions with precise data.”
CBD derived from hemp is totally legal in the U.S., having been sanctioned by the wide-ranging Farm Bill entered law in late 2018
Financiers might not be happy about Charlotte’s Web spending its time and capital on sponsoring the study. On Tuesday, the business’s shares dropped by nearly 6%, exceeding the decline of the wider stock market.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Charlotte’s Web. The Motley Fool has a disclosure policy.”>
position in any of the stocks discussed.
The Motley Fool advises Charlotte’s Web.
The Motley Fool has a disclosure policy“>